Celgene to look beyond Revlimid at R&D day

During Celgene's R&D day tomorrow--the first it has hosted in five years--the developer will attempt to show analysts that it has a promising drug pipeline beyond Revlimid, its top-selling multiple myeloma drug. Revlimid and its predecessor drug Thalomid accounted for almost 80 percent of the biotech's sales last year. Specifically, Reuters says Celgene will detail its programs for "lung cancer; chemotherapy-induced anemia; multiple myeloma; Crohn's disease, a gastrointestinal disorder; psoriasis, a skin disorder; and psoriatic arthritis."

Analysts are also waiting to see if Celgene will produce data supporting Revlimid as a maintenance treatment for multiple myeloma. That could boost the drug's sales from $1.7 billion in 2009 to $3.8 billion by 2013. The drug is also in clinical trials for chronic lymphocytic leukemia, non-Hodgkin's lymphoma, prostate cancer and colorectal cancer.

- read this item for more

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.